This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1198 entries already.
Jena-based organ-on-chip specialist Dynamic42 has inked a strategic partnership with Ohio Lumex Co., Inc. The Ohio-based company, which is an established provider of life science and analytics solutions, will exclusively distribute Dynamic42’s human 3D-sphaeroid-based organ-on-chip models in the U.S. and Canadian markets.
Only three weeks to go until Europe’s largest event for laboratory automation and drug screening. SLAS Europe 2025, organised by the Society for Laboratory Automation and Screening (SLAS), will take place in Hamburg from 20-22 May. In a series, European Biotechnology Magazine presents the 12 most innovative SMEs today: French Minos Biosciences SAS.
Just three weeks to go until Europe’s largest event for laboratory automation and drug screening. SLAS Europe 2025, organised by the Society for Laboratory Automation and Screening (SLAS), will take place from 20-22 May in Hamburg, Germany. In a series, European Biotechnology presents the 12 most innovative SMEs. Today: Nanoworx BV.
Only three weeks to go until Europe’s largest event for laboratory automation and drug screening. SLAS Europe 2025, organised by the Society for Laboratory Automation and Screening (SLAS), will take place in Hamburg from 20-22 May. In a series, European Biotechnology Magazine presents the 12 most innovative SMEs today: UK-based Nanovery Ltd
A team led by Imperial College London has launched a miniature lab into Earth orbit to test the production of edible proteins in space with the help of yeast-based biotech.
A new biomarker for Parkinson’s disease makes it possible to recognise and treat the hereditary dopamine deficiency before the mid-brain is damaged, reports University Bochum spin-out betaSense GmbH.
Barcelona-based epigentics specialist Oryzon Genomics, SA, a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the successful completion has completed an oversubscribed €30m capital increase through issuing 12,765,958 new shares, priced at €2.35 per share.
Cytovation ASA has baged US$6m to advance Phase II development of its bi-specific pore-forming peptide candidate CY-101 in patients with adrenocortical carcinoma.
RWK Bidco AB, newly founded by the private equity firm KKR (Kohlberg Kravis Roberts & Co.), has identified Swedish separation specialist Biotage AB as a takeover target and submitted an official takeover offer.
Boehringer Ingelheim and synthetic lethality specialist Tessellate Bio have entered into an €500m biobucks global license agreement on oral first-in-class cancer treatments.